Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
Lisa Zimmer(The University of Sydney), Dirk Schadendorf(National Center for Tumor Diseases), Jan C. Simon(University Hospital Leipzig), Jochen Utikal(German Cancer Research Center), Bastian Schilling(Goethe University Frankfurt), Rudolf Herbst(Helios Klinikum Erfurt), Klaus Griewank(Düsseldorf University Hospital), Julia Vaübel(University of Duisburg-Essen), Eckhart Kämpgen(Universitätsklinikum Erlangen), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Axel Hauschild(University Hospital Schleswig-Holstein), Elisabeth Livingstone(German Cancer Research Center), Leonie Bluhm, Michael Fluck(Fachklinik Hornheide), Claus Garbe(University of Tübingen), Rainer Rompel, Alexander Enk(Heidelberg University)
Cited by 292
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k